Skip to main content
Journal of Personalized Medicine logoLink to Journal of Personalized Medicine
. 2023 Jul 10;13(7):1118. doi: 10.3390/jpm13071118

Optical Coherence Tomography Assessment of Macular Thickness in Alzheimer’s Dementia with Different Neuropsychological Severities

Chia-Chen Kao 1,2, Hui-Min Hsieh 3,4,5,6,7, Yo-Chen Chang 1,2,8, Hui-Chen Chu 1, Yuan-Han Yang 9,10,11,12,*, Shwu-Jiuan Sheu 1,2,*
Editor: Yousif Subhi
PMCID: PMC10381874  PMID: 37511731

Abstract

This retrospective case-control study aimed to investigate associations between disease severity of Alzheimer’s dementia (AD) and macular thickness. Data of patients with AD who were under medication (n = 192) between 2013 and 2020, as well as an age- and sex-matched control group (n = 200) with normal cognitive function, were included. AD patients were divided into subgroups according to scores of the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). Macular thickness was analyzed via the Early Treatment Diabetic Retinopathy Study (ETDRS) grid map. AD patients had significant reductions in full macula layers, including inner circle, outer inferior area, and outer nasal area of the macula. Similar retinal thinning was noted in ganglion cells and inner plexiform layers. Advanced AD patients (MMSE score < 18 or CDR ≥ 1) showed more advanced reduction of macular thickness than the AD group (CDR = 0.5 or MMSE ≥ 18), indicating that severe cognitive impairment was associated with thinner macular thickness. Advanced AD is associated with significant macula thinning in full retina and inner plexiform layers, especially at the inner circle of the macula. Macular thickness may be a useful biomarker of AD disease severity. Retinal imaging may be a non-invasive, low-cost surrogate for AD.

Keywords: Alzheimer’s dementia (AD), Clinical Dementia Rating (CDR), ganglion cell layer (GCL), inner plexiform layer (IPL), macular thickness, MMSE (Mini-Mental State Examination), nerve fiber layer (NFL), optical coherence tomography (OCT)

1. Introduction

Alzheimer’s dementia (AD) is a progressive neurodegenerative disorder that is the most common cause of dementia [1]. Currently, at least 44 million people are estimated to live with dementia worldwide, which is predicted to more than triple by 2050 as the population ages [2]. A definitive diagnosis of AD is based on amyloid β and tau pathology determined by invasive procedures [3].

Brain imaging, including magnetic resonance imaging (MRI) and positron emission tomography (PET), cerebrospinal fluid (CSF) biomarkers such as amyloid beta (Aβ) and tau, and serologic testing, including genetic markers, are reported to have diagnostic value [4]. However, routine use of these measures in clinical practice has limitations, including high cost, invasiveness, and limited sensitivity and specificity. Thus, AD remains primarily a clinical diagnosis. Currently, AD is diagnosed mainly by characteristic medical history, clinical neurological presentation, and cognitive examinations. However, cognitive assessment of AD using the Mini-Mental State Examination (MMSE) score and Clinical Dementia Rating (CDR) score is time-consuming and reaching diagnostic accuracy is difficult, even by experts [4].

The retina is an integral part of the central nervous system, and the concept of the retina as a surrogate of the brain has received increasing interest in recent years [5]. Retinal spectral-domain optical coherence tomography (OCT) scanning is a non-invasive, widely available imaging test used by ophthalmologists. It demonstrates retinal imaging at the histological level and enables additional reproducible dimensions of the retinal layer along with resolution of 1–2 microns. Two of the most performed OCT scans are the macular scan, which detects retinal pathologies, and the optic nerve head (ONH) scan of the retinal nerve fiber layer (RNFL). Since the retinal ganglion cell layer (GCL) and the ONH RNFL contain the neuronal body and axons connecting photoreceptors with visual pathways in the brain, degenerative changes in the brain have been reported to be detected by OCT scans. OCT complies with a wide variety of sustained studies released in prior years, revealing that cognitive impairment was related to decreased thickness of RNFL, GCL, and full macula layers [6]. Therefore, OCT has great potential to serve as a disease biomarker for AD [7].

The primary aim of the present study was to analyze the associations between the disease severity of Alzheimer’s dementia and macular thickness through retinal OCT images. We aimed to identify the decisive retinal layer and sectors of the retina for detection of AD, and we also correlated the results with clinical cognitive exams, including the MMSE and CDR scores. The study also demonstrates the possibility that macular OCT may address several clinically pertinent challenges in dealing with AD, including disease screening and the evaluation of AD disease severity.

2. Materials and Methods

2.1. Study Design and Data Sources

This retrospective case-control study extracted data from the hospital electronic medical records of Kaohsiung Medical University Hospital Database (KMUHRD), which includes various patient medical records from one medical center, two regional hospitals, and one local hospital in southern Taiwan. The KMUHRD data used in this study included patient data of outpatient visits, inpatient hospitalization, retinal spectral-domain OCT imaging and reports, and patient neuropsychological examination reports.

2.2. Ethical Considerations

The Institutional Review Board (IRB) and Ethics Committee of Kaohsiung Medical University Hospital reviewed and approved the study protocol, which also adheres to the Declaration of Helsinki. Since this study was retrospective in design and used existing patient information that was deidentified, the IRB also waived patients’ informed consent.

2.3. Study Sample

Patients diagnosed with AD based on ICD-9-CM and ICD-10 diagnosis codes and who received prescribed medication by neurologists between 2013 and 2020 in one medical center and one regional hospital of the KMUHRD database were included. The cognitive examination was obtained from the department of Neurology. Patients with diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), glaucoma, optic neuropathy, and ocular disease that may lead to significant changes in retinal thickness were excluded.

The included patients had records of OCT exams at ophthalmic visits, as well as OCT images taken close to the date of AD diagnosis within the time interval of 1–2 years. OCT images were generated by the Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany). Initial quality control was performed by experienced ophthalmologists and technicians during the clinical OCT examination, to filter out images with low resolution or improper format as well as eyes with age-related macular disease (AMD), macular holes (MH), VMT (vitreomacular traction), and epiretinal membrane (ERM), even chorioretinal atrophy or prominent posterior staphyloma. Precise matching of patients’ age (by birth year) and sex was done to generate the comparison group (control group) of non-AD patients. Patients receiving OCT exams between 2013 and 2020, filtered by the exclusion criteria cited above, were included. Of these patients, under initial matching with sex and age and exclusion of outliers, 175 patients had AD under medication and 188 patients had no cognitive impairment. Figure 1 shows the study sample inclusion and exclusion algorithm of the study.

Figure 1.

Figure 1

The algorithm of study design. OCT: optical coherence tomography; N: numbers of patients; KMUHRD: Kaohsiung Medical University Hospital Database; MMSE: Mini-Mental State Examination; CDR: Clinical Dementia Rating.

2.4. Measurements

The data augmentation procedure was performed by exporting the macular thickness map into different retinal layers, including full layers of macula, nerve fiber layer, ganglion cell layer, and inner plexiform layer, in the total four categories of thickness map. The entire thickness map was exported into the Early Treatment Diabetic Retinopathy Study (ETDRS) grid map, which was divided into nine sectors (one 1-millimeter-diameter circle at the center, four inner-quarter annuluses between the 1- and 3-millimeter-diameter circles, and four outer-quarter annuluses between the 3- and 6-millimeter diameter circles), as previously described [8]. Figure 2 showed the ETDRS grid map adapted from previous studies [9,10], and abbreviations and numbers were employed to represent the nine regions of macular thickness map in the present study.

Figure 2.

Figure 2

The adapted Early Treatment Diabetic Retinopathy Study (ETDRS) grid map.

2.5. Subgroup Analysis

Patients with AD were then divided into subgroups according to MMSE scores and CDR scores (Figure 1). MMSE is an exam of cognitive function, including orientation, concentration, attention, verbal memory, naming, and visuospatial skills. The exam is based on a total score of 30 points, and the better cognitive function is related to a higher score. As for CDR, it is rated according to six domains of cognitive function, including memory, orientation, judgment, problem solving, community affairs, home and hobbies, and personal care. The result is integrated into a 5-point scale as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. Given that no standardized MMSE cutoff values for dementia staging were available, we followed previous studies and classified AD patients into mild cognitive impairment (MMSE score ≥ 18) and moderate or severe impaired cognitive function (MMSE < 18) [11,12]. Because staging was based on CDR scores, patients were classified into one group with more severe cognitive impairment (CDR ≥ 1) and one group with mild cognitive impairment (CDR < 1). For those AD patients without MMSE or CDR records in the database, another group was classified as the group with missing data. The characteristics of age and sex among the three subgroups based on MMSE scores or CDR scores are presented in Appendix A, Table A1. Specifically, 87 patients who had MMSE scores ≥ 18, 37 patients with MMSE scores < 18, and 51 patients with missing MMSE data were recorded. In the CDR-based group, 58 patients with CDR = 0.5, 48 patients with CDR ≥ 1, and 69 patients with missing data were reported. Multivariable linear regression models were used later to analyze the associations between macular thickness and MMSE as well as CDR.

2.6. Statistical Analysis

Frequencies were used to present the proportions of demographic characteristics. Chi-square tests were used to compare differences between categorical variables. We first did the hypothesis testing for normality for the measures of ETDRS grid macular thickness using the Anderson-Darling test [13], which is one of the common approaches for the normality test, and the results supported the assumptions of normal distribution. We then used independent t-tests or ANOVA tests to compare continuous variables between groups. Multivariable linear regression models were used to compare the differences in ETDRS grid macular thickness between groups (AD versus controls, and different severity level of dementia based on MMSE and CDR) while controlling for age and sex. A two-tailed p < 0.05 was considered significant in all statistical tests. We further used the Bonferroni approach to calculate adjusted p-values among multiple site comparisons to handle multiple testing concerns [14]. All statistical operations were performed using SAS version 9.4 (SAS Analytics, Cary, NC, USA).

3. Results

3.1. Demographic Characteristics of the Participants

Table 1 shows the baseline demographic characteristics of age (based on birth year) and sex between matched AD patients (N = 175) and the comparison group (N = 188). No statistically significant differences were noted between these two groups. For AD patients, the mean age was 77.144 years with 65.14% older than 75 years, and 61.14% were female. For the non-AD comparison group, the mean age was 76.76 years with 62.23% older than 75 years, and 61.70% were female. MMSE and CDR scores among AD patients are also presented in Table 1.

Table 1.

General characteristics of the participants. N: numbers of patients; y/o: years-old, MMSE: Mini-Mental State Examination, CDR: Clinical Dementia Rating, SD: standard deviation; 95% CI: 95% confidence interval; p-value < 0.05 is considered as statistically significant.

Alzheimer’s Dementia (AD) Control Group
N, %/Mean ± SD N, %/Mean ± SD p-Value
N N = 175 N = 188
Average Age (y/o) 77.14 ± 10.51 76.76 ± 10.46 0.725
<65 16 (9.14%) 16 (8.51%) 0.751
65~74 45 (25.71%) 55 (29.26%)
≥75 114 (65.14%) 117 (62.23%)
Gender
Male 68 (38.86%) 72 (38.30%) 0.913
Female 107 (61.14%) 116(61.7%)
Average MMSE Score 20.60 ± 5.49
MMSE, Category
≥18 87 (49.71%)
<18 37 (21.14%)
No Data 51 (29.14%)
CDR, Category
0.5 58 (33.14%)
1 37 (21.14%)
2,3 11 (6.29%)
No Data 69 (39.43%)

3.2. Association between Macular Thickness and Alzheimer’s Dementia

As shown in Table 2, retinal thickness was thinner in patients with AD in comparison to the control group with normal cognitive function. In the full macula layers, significant differences were observed between the groups in the inner superior (case: 322.90 ± 16.43 μm, control 329.00 ± 14.88 μm; beta coefficient: −7.03; p-value < 0.001), inner temporal area (case: 311.30 ± 15.89 μm, control 315.80 ± 14.76 μm; beta coefficient: −5.32; p-value = 0.005), inner inferior area (case: 319.00 ± 17.12 μm, control 324.50 ± 16.02 μm; beta coefficient: −7.00; p-value = 0.001), inner nasal area (case: 326.50 ± 17.62 μm, control 331.70 ± 16.58 μm; beta coefficient: −6.55; p-value = 0.004), outer inferior area (case: 272.60 ± 14.30 μm, control 2276.30 ± 12.56 μm; beta coefficient: −3.80; p-value = 0.011), and outer nasal area (case: 298.90 ± 15.84 μm, control 302.20 ± 14.56 μm; beta coefficient: −4.49; p-value = 0.043). The results were similar in the inner plexiform layer (IPL) and ganglion cell layer (GCL), which showed significantly decreased macular thickness in AD, especially in the inner circle part and outer inferior area in the ETDRS grid. However, when the data were defined solely on the NFL layer, no significant differences were noted in macular thickness between the AD group and the control group. Thus, when we converted the statistical results into plots of the ETDRS grid map, the area marked with a star represented a significant reduction of macular thickness in different retinal layers in AD (Figure 3).

Table 2.

Characteristics of ETDRS grid macular thickness in Alzheimer’s dementia (AD) and control group. NFL: nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; GCC: ganglion cell complex (NFL + GCL + IPL); N: numbers of patients; SD: standard deviation; 95% CI: 95% confidence interval; p-value < 0.05 is considered as statistically significant (*), and the bold numbers mean statistically significance with p-value < 0.05.

Alzheimer’s Dementia (AD) Control Multivariable Linear Regression a
N,%/Mean ± SD N,%/Mean ± SD p-Value β (95% CI) p-Value Bonferroni
p-Value
N N = 175 N = 188
Full thickness, μm
 central 257.70 ± 20.94 259.90 ± 21.25 0.329 −1.88 (−6.24, 2.48) 0.316 1.000
 inner superior 322.90 ± 16.43 329.00 ± 14.88 <0.001 * −7.03 (−10.67, −3.39) <0.001 * 0.002 *
 inner temporal 311.30 ± 15.89 315.80 ± 14.76 0.005 * −5.32 (−8.68, −1.96) 0.005 * 0.042 *
 inner inferior 319.00 ± 17.12 324.50 ± 16.02 0.002 * −7.00 (−10.71, −3.28) 0.001 * 0.013 *
 inner nasal 326.50 ± 17.62 331.70 ± 16.58 0.004 * −6.55 (−10.28, −2.83) 0.004 * 0.032 *
 outer superior 283.60 ± 14.72 284.60 ± 12.99 0.520 −2.24 (−5.28, 0.81) 0.549 1.000
 outer temporal 269.90 ± 13.48 270.90 ± 11.76 0.459 −1.80 (−4.53, 0.93) 0.476 1.000
 outer inferior 272.60 ± 14.30 276.30 ± 12.56 0.010 * −3.80 (−7.06, −0.54) 0.011 * 0.096
 outer nasal 298.90 ± 15.84 302.20 ± 14.56 0.039 * −4.49 (−7.85, −1.12) 0.043 * 0.386
NFL thickness, μm
 central 11.59 ± 2.37 11.79 ± 2.47 0.423 −0.06 (−0.58, 0.46) 0.426 1.000
 inner superior 25.26 ± 4.32 25.62 ± 3.98 0.409 −0.43 (−1.34, 0.48) 0.411 1.000
 inner temporal 18.66 ± 1.96 18.46 ± 1.62 0.293 0.21 (−0.15, 0.57) 0.313 1.000
 inner inferior 24.43 ± 4.14 24.52 ± 3.67 0.832 −0.19 (−0.99, 0.62) 0.853 1.000
 inner nasal 21.63 ± 3.01 21.66 ± 2.59 0.918 −0.03 (−0.61, 0.55) 0.914 1.000
 outer superior 38.99 ± 6.79 39.23 ± 5.94 0.720 −0.38 (−1.75, 0.98) 0.725 1.000
 outer temporal 21.01 ± 2.61 20.64 ± 1.72 0.123 0.34 (−0.10, 0.78) 0.127 1.000
 outer inferior 38.48 ± 8.30 38.48 ± 7.58 0.999 −0.03 (−1.68, 1.62) 0.962 1.000
 outer nasal 48.99 ± 8.73 49.28 ± 8.29 0.747 −0.58 (−2.36, 1.19) 0.771 1.000
GCL thickness, μm
 central 13.84 ± 4.47 13.79 ± 4.33 0.909 0.58 (−0.51, 1.67) 0.892 1.000
 inner superior 46.86 ± 5.83 48.70 ± 6.66 0.005 * −2.40 (−3.81, −0.99) 0.006 * 0.052
 inner temporal 41.38 ± 6.35 42.77 ± 6.58 0.041 * −1.40 (−2.76, −0.03) 0.044 * 0.397
 inner inferior 45.42 ± 6.31 47.04 ± 6.60 0.017 * −1.92 (−3.39, −0.46) 0.018 * 0.160
 inner nasal 45.86 ± 6.58 47.54 ± 7.55 0.025 * −1.89 (−3.36, −0.42) 0.026 * 0.237
 outer superior 31.55 ± 4.41 32.00 ± 3.68 0.298 −0.84 (−1.70, 0.02) 0.310 1.000
 outer temporal 32.35 ± 4.84 32.36 ± 4.25 0.988 −0.29 (−1.28, 0.70) 0.985 1.000
 outer inferior 30.02 ± 4.12 30.97 ± 3.71 0.021 * −0.74 (−1.63, 0.16) 0.022 * 0.197
 outer nasal 35.30 ± 4.11 35.96 ± 4.10 0.124 −0.81 (−1.67, 0.06) 0.133 1.000
IPL thickness, μm
 central 19.11 ± 3.82 19.34 ± 3.54 0.558 0.05 (−0.76, 0.86) 0.563 1.000
 inner superior 37.01 ± 3.70 38.24 ± 4.20 0.003 * −1.55 (−2.44, −0.67) 0.003 * 0.030 *
 inner temporal 37.47 ± 4.30 38.77 ± 4.25 0.004 * −1.38 (−2.27, −0.49) 0.004 * 0.037 *
 inner inferior 36.42 ± 4.01 37.38 ± 4.15 0.027 * −1.09 (−1.99, −0.18) 0.028 * 0.250
 inner nasal 38.16 ± 4.05 39.31 ± 4.82 0.014 * −1.33 (−2.27, −0.38) 0.016 * 0.140
 outer superior 25.77 ± 2.98 25.98 ± 2.71 0.465 −0.45 (−1.05, 0.15) 0.495 1.000
 outer temporal 29.91 ± 3.07 30.16 ± 2.91 0.424 −0.43 (−1.07, 0.20) 0.448 1.000
 outer inferior 24.51 ± 2.87 25.26 ± 2.62 0.010 * −0.67 (−1.29, −0.06) 0.010 * 0.092
 outer nasal 27.01 ± 3.05 27.64 ± 2.99 0.047 * −0.69 (−1.31, −0.07) 0.051 0.460
NFL + GCL thickness, μm
 central 25.43 ± 6.36 25.58 ± 6.47 0.823 0.52 (−1.01, 2.05) 0.837 1.000
 inner superior 72.11 ± 8.90 74.32 ± 9.37 0.022 * −2.83 (−4.87, −0.79) 0.025 * 0.221
 inner temporal 60.03 ± 6.67 61.23 ± 6.77 0.092 −1.19 (−2.64, 0.27) 0.097 0.877
 inner inferior 69.85 ± 9.34 71.56 ± 9.35 0.082 −2.11 (−4.19, −0.03) 0.087 0.782
 inner nasal 67.49 ± 8.49 69.20 ± 9.15 0.066 −1.92 (−3.77, −0.07) 0.070 0.633
 outer superior 70.54 ± 9.58 71.23 ± 8.32 0.466 −1.22 (−3.16, 0.72) 0.478 1.000
 outer temporal 53.36 ± 6.11 53.01 ± 5.05 0.549 0.05 (−1.17, 1.27) 0.544 1.000
 outer inferior 68.50 ± 10.92 69.45 ± 9.89 0.383 −0.77 (−3.00, 1.46) 0.409 1.000
 outer nasal 84.29 ± 10.54 85.24 ± 10.32 0.385 −1.39 (−3.63, 0.85) 0.410 1.000
GCL + IPL thickness, μm
 central 32.95 ± 8.04 33.12 ± 7.53 0.832 0.63 (−1.21, 2.47) 0.844 1.000
 inner superior 83.86 ± 9.03 86.95 ± 10.38 0.003 * −3.95 (−6.17, −1.74) 0.003 * 0.026 *
 inner temporal 78.85 ± 10.10 81.54 ± 10.31 0.013 * −2.77 (−4.93, −0.62) 0.013 * 0.117
 inner inferior 81.84 ± 9.92 84.42 ± 10.35 0.016 * −3.01 (−5.30, −0.72) 0.016 * 0.147
 inner nasal 84.02 ± 10.12 86.85 ± 11.82 0.015 * −3.22 (−5.53, −0.90) 0.016 * 0.142
 outer superior 57.32 ± 7.14 57.98 ± 6.19 0.343 −1.29 (−2.71, 0.13) 0.364 1.000
 outer temporal 62.26 ± 7.63 62.52 ± 6.57 0.731 −0.72 (−2.27, 0.82) 0.759 1.000
 outer inferior 54.53 ± 6.77 56.23 ± 6.14 0.012 * −1.41 (−2.88, 0.06) 0.013 * 0.117
 outer nasal 62.30 ± 6.80 63.60 ± 6.88 0.072 −1.50 (−2.93, −0.07) 0.078 0.698
NFL + IPL thickness, μm
 central 30.70 ± 5.85 31.13 ± 5.71 0.478 −0.01 (−1.28, 1.26) 0.482 1.000
 inner superior 62.26 ± 6.91 63.86 ± 7.13 0.031 * −1.98 (−3.54, −0.43) 0.034 * 0.304
 inner temporal 56.13 ± 4.80 57.22 ± 4.60 0.027 * −1.17 (−2.17, −0.17) 0.028 * 0.248
 inner inferior 60.86 ± 7.27 61.90 ± 6.99 0.165 −1.27 (−2.81, 0.27) 0.175 1.000
 inner nasal 59.79 ± 6.23 60.97 ± 6.51 0.079 −1.36 (−2.71, 0.00) 0.084 0.752
 outer superior 64.75 ± 8.36 65.21 ± 7.44 0.581 −0.84 (−2.55, 0.88) 0.597 1.000
 outer temporal 50.91 ± 4.60 50.80 ± 3.82 0.803 −0.09 (−1.00, 0.81) 0.803 1.000
 outer inferior 62.99 ± 9.97 63.74 ± 8.86 0.448 −0.70 (−2.69, 1.29) 0.476 1.000
 outer nasal 75.99 ± 9.89 76.91 ± 9.38 0.363 −1.28 (−3.32, 0.76) 0.386 1.000
NFL + GCL + IPL thickness, μm
 central 44.54 ± 9.96 44.91 ± 9.68 0.714 0.57 (−1.72, 2.85) 0.725 1.000
 inner superior 109.10 ± 11.93 112.60 ± 12.98 0.009 * −4.38 (−7.19, −1.58) 0.010 * 0.089
 inner temporal 97.51 ± 10.33 99.99 ± 10.45 0.023 * −2.56 (−4.79, −0.34) 0.024 * 0.219
 inner inferior 106.30 ± 12.87 108.90 ± 13.00 0.050 −3.20 (−6.09, −0.31) 0.053 0.477
 inner nasal 105.70 ± 12.02 108.50 ± 13.38 0.033 * −3.25 (−5.94, −0.56) 0.035 * 0.317
 outer superior 96.31 ± 11.75 97.21 ± 10.33 0.436 −1.67 (−4.07, 0.73) 0.453 1.000
 outer temporal 83.27 ± 8.78 83.16 ± 7.34 0.903 −0.38 (−2.15, 1.39) 0.888 1.000
 outer inferior 93.01 ± 13.05 94.71 ± 11.66 0.189 −1.44 (−4.12, 1.24) 0.204 1.000
 outer nasal 111.30 ± 12.36 112.90 ± 12.13 0.218 −2.09 (−4.72, 0.55) 0.236 1.000

Note: a: Age and sex were controlled and adjusted in the multiple variable regression models.

Figure 3.

Figure 3

In the ETDRS grid map, the color-coded sectors showed significant decreased macular thickness in different retina layers in Alzheimer’s dementia. C: center; IS: inner superior; IT: inner temporal; II: inner inferior; IN: inner nasal; OS: outer superior; OT: outer temporal; OI: outer inferior; ON: outer nasal.

When any one of the single layers, including NFL, GCL, and IPL, was statistically integrated to another one, or when the three single layers were all statistically combined, the results were similar, presenting significantly thinner thickness in the inner part of the macula in AD than in the control group. In addition, according to the Bonferroni approach to calculate adjusted p-values, the significant differences were noted in the inner area of macula in full thickness, IPL layer, and in GCL + IPL layer.

3.3. Associations between Macular Thickness and Severity of Dementia via Subgroup Analysis Stratified by MMSE and CDR Scores

In the initial results of MMSE subgroup analysis, significant differences were found in macular thickness in between-group comparisons, but the results were not consistent (Appendix B). After multivariable linear regression, when compared to the control group, group 2, with MMSE scores < 18, showed no significant reduction in any layer of macula thickness, and group 1, with MMSE ≥ 18, showed significantly thinner full macular thickness in the inner superior region (−6.00 µm (95%CI: −9.83, −2.17), Bonferronip-value 0.021) (Table 3). In the missing data group, the macular thickness was thinner than that in the control group in full layers of the retina, NFL, GCL, or IPL, and in almost every region of the macula.

Table 3.

ETDRS grid macular thickness stratified by MMSE scores. MMSE: Mini-Mental State Examination; NFL: nerve fiber layer; GCL: ganglion cell layer; IPL: inner plexiform layer; GCC: ganglion cell complex (NFL + GCL + IPL); N: numbers of patients; SD: standard deviation; 95% CI: 95% confidence interval; p-value is < 0.05 considered as statistically significant (*), and the bold numbers mean statistically significance with p-value < 0.05.

Multivariable Linear Regression
Group 1 vs. Control Group 2 vs. Control Group 3 vs. Control
β (95% CI) p-Value Bonferroni
p-Value
β (95% CI) p-Value Bonferroni
p-Value
β (95% CI) p-Value Bonferroni
p-Value
N N = 87 N = 37 N = 51
Full, μm
 C −1.45 (−6.70, 3.80) 0.587 1.000 −2.45 (−10.01, 5.10) 0.523 1.000 −2.87 (−9.09, 3.36) 0.365 1.000
 IS −6.00 (−9.83, −2.17) 0.002 * 0.021 * −3.31 (−8.54, 1.92) 0.214 1.000 −8.23 (−12.79, −3.66) <0.001 * 0.004 *
 IT −3.41 (−7.07, 0.26) 0.068 0.616 −2.70 (−7.82, 2.42) 0.300 1.000 −7.32 (−11.81, −2.83) 0.002 * 0.012 *
 II −4.62 (−8.66, −0.58) 0.025 * 0.225 −0.74 (−6.20, 4.73) 0.791 1.000 −10.03 (−14.71, −5.36) <0.001 * 0.001 *
 IN −5.10 (−9.35, −0.85) 0.019 * 0.171 −0.34 (−6.03, 5.35) 0.907 1.000 −8.43 (−13.25, −3.62) <0.001 * 0.006 *
 OS −1.47 (−4.81, 1.87) 0.387 1.000 3.69 (−0.97, 8.34) 0.120 1.000 −3.16 (−7.38, 1.06) 0.141 1.000
 OT −1.12 (−4.12, 1.88) 0.464 1.000 1.84 (−2.37, 6.04) 0.390 1.000 −2.55 (−6.38, 1.27) 0.190 1.000
 OI −2.96 (−6.14, 0.22) 0.068 0.616 −0.39 (−4.99, 4.21) 0.867 1.000 −6.91 (−10.94, −2.89) 0.001 * 0.006 *
 ON −2.00 (−5.74, 1.73) 0.292 1.000 −0.15 (−5.28, 4.99) 0.955 1.000 −7.38 (−11.83, −2.93) 0.001 * 0.010 *
NFL, μm
 C −0.32 (−0.92–0.29) 0.301 1.000 −0.19 (−1.05, 0.68) 0.672 1.000 0.04 (−0.72, 0.79) 0.920 1.000
 IS 0.05 (−1.01–1.10) 0.927 1.000 −0.39 (−1.79, 1.02) 0.589 1.000 −1.03 (−2.31, 0.24) 0.112 1.000
 IT −0.10 (−0.50–0.29) 0.614 1.000 0.51 (−0.07, 1.09) 0.086 0.774 0.42 (−0.13, 0.97) 0.131 1.000
 II −0.28 (−1.23–0.66) 0.555 1.000 1.38 (0.08, 2.69) 0.038 0.344 −0.73 (−1.86, 0.40) 0.207 1.000
 IN 0.01 (−0.68–0.70) 0.976 1.000 0.48 (−0.44, 1.40) 0.307 1.000 −0.46 (−1.26, 0.33) 0.251 1.000
 OS 0.11 (−1.42–1.63) 0.892 1.000 1.87 (−0.29, 4.02) 0.090 0.812 −2.33 (−4.28, −0.38) 0.019 * 0.175
 OT 0.29 (−0.17–0.75) 0.221 1.000 0.82 (0.18, 1.46) 0.013 0.114 0.13 (−0.57, 0.83) 0.718 1.000
 OI 0.11 (−1.80–2.01) 0.914 1.000 2.33 (−0.55, 5.22) 0.113 1.000 −1.70 (−4.02, 0.61) 0.148 1.000
 ON 0.71 (−1.37–2.78) 0.503 1.000 2.49 (−0.52, 5.50) 0.104 0.935 −3.79 (−6.39, −1.19) 0.004 * 0.040 *
GCL, μm
 C 0.05 (−1.06–1.15) 0.934 1.000 0.29 (−1.29, 1.87) 0.719 1.000 −0.08 (−1.40, 1.25) 0.907 1.000
 IS −1.57 (−3.13–0.00) 0.049 0.445 −0.13 (−2.41, 2.15) 0.908 1.000 −3.35 (−5.35, −1.35) 0.001 * 0.010 *
 IT −0.34 (−1.92–1.23) 0.666 1.000 −0.94 (−3.18, 1.29) 0.406 1.000 −3.32 (−5.32, −1.32) 0.001 * 0.011 *
 II −1.20 (−2.76–0.36) 0.132 1.000 −0.05 (−2.32, 2.22) 0.966 1.000 −3.35 (−5.31, −1.38) <0.001 * 0.008 *
 IN −1.51 (−3.29–0.26) 0.095 0.853 0.44 (−2.09, 2.98) 0.731 1.000 −3.23 (−5.42, −1.04) 0.004 * 0.036 *
 OS −0.26 (−1.22–0.71) 0.602 1.000 1.14 (−0.19, 2.47) 0.092 0.825 −1.82 (−3.02, −0.63) 0.003 * 0.026 *
 OT 0.16 (−0.91–1.23) 0.767 1.000 0.94 (−0.63, 2.51) 0.241 1.000 −0.94 (−2.36, 0.48) 0.195 1.000
 OI −0.82 (−1.79–0.14) 0.095 0.855 −1.02 (−2.38, 0.34) 0.141 1.000 −1.09 (−2.24, 0.07) 0.065 0.582
 ON −0.44 (−1.42–0.55) 0.382 1.000 0.06 (−1.36, 1.48) 0.933 1.000 −1.47 (−2.76, −0.18) 0.026 * 0.230
IPL, μm
 C −0.16 (−1.08–0.77) 0.740 1.000 −0.31 (−1.59, 0.98) 0.639 1.000 −0.23 (−1.32, 0.87) 0.682 1.000
 IS −1.23 (−2.22–−0.24) 0.015 0.139 −0.45 (−1.86, 0.95) 0.524 1.000 −1.65 (−2.89, −0.41) 0.009 * 0.084
 IT −0.93 (−1.95–0.08) 0.072 0.651 −1.04 (−2.47, 0.39) 0.153 1.000 −1.90 (−3.20, −0.59) 0.005 * 0.041 *
 II −0.75 (−1.74–0.24) 0.135 1.000 −0.09 (−1.48, 1.30) 0.902 1.000 −1.76 (−2.99, −0.53) 0.005 * 0.048 *
 IN −1.00 (−2.13–0.14) 0.084 0.760 −0.53 (−2.12, 1.06) 0.511 1.000 −1.67 (−3.08, −0.26) 0.021 * 0.186
 OS −0.07 (−0.77–0.63) 0.844 1.000 0.85 (−0.11, 1.82) 0.084 0.753 −1.17 (−2.00, −0.33) 0.006 * 0.058
 OT −0.14 (−0.85–0.56) 0.692 1.000 0.42 (−0.63, 1.48) 0.429 1.000 −0.84 (−1.78, 0.10) 0.081 0.725
 OI −0.59 (−1.26–0.08) 0.082 0.736 −0.51 (−1.45, 0.44) 0.292 1.000 −1.16 (−2.01, −0.31) 0.008 * 0.068
 ON −0.37 (−1.11–0.36) 0.315 1.000 −0.14 (−1.18, 0.90) 0.785 1.000 −1.35 (−2.29, −0.40) 0.006 * 0.050
NFL + GCL,
 C −0.27 (−1.88–1.34) 0.740 1.000 0.10 (−2.21, 2.42) 0.930 1.000 −0.04 (−2.01, 1.93) 0.968 1.000
 IS −1.52 (−3.81–0.78) 0.194 1.000 −0.52 (−3.77, 2.73) 0.753 1.000 −4.38 (−7.28, −1.49) 0.003 * 0.029 *
 IT −0.45 (−2.07–1.18) 0.590 1.000 −0.44 (−2.78, 1.91) 0.715 1.000 −2.90 (−5.00, −0.79) 0.007 * 0.065
 II −1.48 (−3.74–0.78) 0.198 1.000 1.33 (−1.89, 4.56) 0.416 1.000 −4.07 (−6.84, −1.30) 0.004 * 0.037 *
 IN −1.50 (−3.72–0.72) 0.183 1.000 0.92 (−2.19, 4.03) 0.560 1.000 −3.69 (−6.37, −1.02) 0.007 * 0.062
 OS −0.15 (−2.23–1.93) 0.887 1.000 3.01 (0.01, 6.01) 0.049 0.445 −4.15 (−6.91, −1.40) 0.003 * 0.030 *
 OT 0.45 (−0.83–1.72) 0.491 1.000 1.75 (−0.14, 3.65) 0.069 0.624 −0.81 (−2.59, 0.97) 0.371 1.000
 OI −0.72 (−3.24–1.80) 0.576 1.000 1.31 (−2.41, 5.03) 0.488 1.000 −2.79 (−5.82, 0.24) 0.071 0.638
 ON 0.27 (−2.22–2.75) 0.833 1.000 2.55 (−1.15, 6.25) 0.175 1.000 −5.26 (−8.48, −2.05) 0.001 * 0.013 *
GCL + IPL,
 C −0.11 (−2.06–1.84) 0.912 1.000 −0.02 (−2.76, 2.73) 0.990 1.000 −0.31 (−2.62, 2.01) 0.794 1.000
 IS −2.79 (−5.23–−0.36) 0.025 * 0.223 −0.59 (−4.10, 2.92) 0.741 1.000 −5.00 (−8.07, −1.93) 0.002 * 0.014 *
 IT −1.28 (−3.73–1.18) 0.307 1.000 −1.98 (−5.46, 1.49) 0.262 1.000 −5.22 (−8.33, −2.10) 0.001 * 0.010 *
 II −1.95 (−4.41–0.50) 0.119 1.000 −0.14 (−3.65, 3.38) 0.939 1.000 −5.11 (−8.14, −2.07) 0.001 * 0.010 *
 IN −2.51 (−5.30–0.27) 0.077 0.689 −0.09 (−4.03, 3.85) 0.965 1.000 −4.90 (−8.30, −1.49) 0.005 * 0.045 *
 OS −0.33 (−1.95–1.29) 0.692 1.000 2.00 (−0.24, 4.23) 0.080 0.716 −2.99 (−4.93, −1.05) 0.003 * 0.023 *
 OT 0.02 (−1.63–1.67) 0.981 1.000 1.36 (−1.08, 3.80) 0.273 1.000 −1.77 (−3.98, 0.43) 0.114 1.000
 OI −1.41 (−3.00–0.17) 0.081 0.725 −1.53 (−3.75, 0.70) 0.178 1.000 −2.25 (−4.18, −0.31) 0.023 * 0.208
 ON −0.81 (−2.47–0.84) 0.335 1.000 −0.08 (−2.47, 2.30) 0.945 1.000 −2.82 (−4.96, −0.68) 0.010 * 0.090
NFL + IPL,
 C −0.47 (−1.92–0.97) 0.518 1.000 −0.49 (−2.53, 1.55) 0.635 1.000 −0.19 (−1.95, 1.57) 0.832 1.000
 IS −1.18 (−2.96–0.60) 0.194 1.000 −0.84 (−3.28, 1.60) 0.497 1.000 −2.68 (−4.90, −0.47) 0.018 * 0.159
 IT −1.03 (−2.15–0.09) 0.071 0.637 −0.53 (−2.09, 1.03) 0.505 1.000 −1.47 (−2.93, −0.01) 0.048 * 0.433
 II −1.04 (−2.74–0.67) 0.233 1.000 1.30 (−1.08, 3.68) 0.284 1.000 −2.49 (−4.59, −0.39) 0.021 * 0.185
 IN −0.99 (−2.60–0.63) 0.231 1.000 −0.05 (−2.25, 2.14) 0.961 1.000 −2.13 (−4.06, −0.20) 0.031 * 0.275
 OS 0.04 (−1.84–1.91) 0.971 1.000 2.72 (0.04, 5.40) 0.047 0.424 −3.50 (−5.92, −1.07) 0.005 * 0.044 *
 OT 0.14 (−0.81–1.09) 0.765 1.000 1.24 (−0.19, 2.67) 0.089 0.805 −0.71 (−2.06, 0.65) 0.304 1.000
 OI −0.49 (−2.74–1.76) 0.670 1.000 1.83 (−1.53, 5.18) 0.284 1.000 −2.86 (−5.61, −0.12) 0.041 * 0.371
 ON 0.33 (−1.96–2.62) 0.777 1.000 2.35 (−1.04, 5.74) 0.174 1.000 −5.14 (−8.07, −2.20) <0.001 * 0.006 *
GCC, μm
 C −0.43 (−2.89–2.03) 0.732 1.000 −0.20 (−3.69, 3.29) 0.909 1.000 −0.27 (−3.24, 2.70) 0.859 1.000
 IS −2.75 (−5.88–0.39) 0.086 0.776 −0.97 (−5.41, 3.46) 0.665 1.000 −6.03 (−9.97, −2.09) 0.003 * 0.025 *
 IT −1.38 (−3.88–1.12) 0.279 1.000 −1.47 (−5.03, 2.08) 0.414 1.000 −4.79 (−8.00, −1.59) 0.004 * 0.032 *
 II −2.23 (−5.36–0.89) 0.160 1.000 1.25 (−3.18, 5.68) 0.580 1.000 −5.83 (−9.66, −2.00) 0.003 * 0.027 *
 IN −2.50 (−5.72–0.72) 0.127 1.000 0.39 (−4.10, 4.88) 0.865 1.000 −5.36 (−9.24, −1.48) 0.007 * 0.062
 OS −0.22 (−2.81–2.37) 0.867 1.000 3.86 (0.14, 7.58) 0.042 * 0.377 −5.32 (−8.68, −1.96) 0.002 * 0.018 *
 OT 0.31 (−1.54–2.15) 0.745 1.000 2.18 (−0.58, 4.93) 0.121 1.000 −1.65 (−4.19, 0.89) 0.203 1.000
 OI −1.31 (−4.29–1.68) 0.389 1.000 0.81 (−3.55, 5.17) 0.715 1.000 −3.95 (−7.57, −0.33) 0.032 * 0.292
 ON −0.11 (−3.00–2.79) 0.942 1.000 2.41 (−1.92, 6.74) 0.274 1.000 −6.61 (−10.38, −2.84) <0.001 * 0.005 *

Note: Age and sex were controlled and adjusted in the multiple variable regression models.

Regarding CDR scores, the initial results showed no significant differences in between-group comparisons (Appendix B). After multivariable linear regression according to the Bonferroni approach to calculate adjusted p-values, in group 2, with CDR scores ≥ 1, significant reduction was observed in the macular thickness compared to that of the control group. The full layer of the retina revealed the most prominent results, especially in the inner superior region (−8.13 µm (95%CI: −12.81, −3.46), Bonferroni p-value = 0.006), inner temporal region (−7.34 µm (95%CI: −11.91, −2.78), Bonferroni p-value 0.015), and inner inferior region (−8.58 µm (95%CI: −13.48, −3.68), Bonferroni p-value = 0.006) (Table 4), and the results were similar in the inner temporal region of the IPL and ganglion cell complex. Interestingly, no significantly thinner macular thickness was found in the NFL layer. In group 1, with CDR < 1, macula thickness was generally decreased but no significant difference was noted via the Bonferroni approach. Macular thickness in the missing data group was thinner when compared to that of the control group, but the greater amount of macular thickness reduction was noted in group 2, with CDR score ≥ 1, rather than in the missing data group. Therefore, these results indicated that the advanced stage of dementia was associated with thinner macular thickness. The association between ETDRS macular thickness of the full retina layer and different groups of neuropsychological severity was presented in Figure 4.

Table 4.

ETDRS grid macular thickness stratified by CDR scores. CDR: clinical dementia rating; NFL: nerve fiber layers; GCL: ganglion cell layer; IPL: inner plexiform layer; GCC: ganglion cell complex (NFL + GCL + IPL); N: numbers of patients; SD: standard deviation; 95% CI: 95% confidence interval; p-value < 0.05 is considered as statistically significant (*), and the bold numbers mean statistically significance with p-value < 0.05.

Multivariable Linear Regression
Group 1 vs. Control Group 2 vs. Control Group 3 vs. Control
β (95% CI) p-Value Bonferroni
p-Value
β (95% CI) p-Value Bonferroni
p-Value
β (95% CI) p-Value Bonferroni
p-Value
N N = 58 N = 48 N = 69
Full, μm
 C −2.74 (−8.76, 3.29) 0.372 1.000 −4.68 (−11.24, 1.88) 0.161 1.000 0.06 (−5.68, 5.80) 0.983 1.000
 IS −4.99 (−9.38, −0.60) 0.026 * 0.235 −8.13 (−12.81, −3.46) 0.001 * 0.006 * −5.48 (−9.61, −1.36) 0.009 * 0.084
 IT −2.22 (−6.42, 1.98) 0.299 1.000 −7.34 (−11.91, −2.78) 0.002 * 0.015 * −4.15 (−8.18, −0.11) 0.044 * 0.398
 II −2.21 (−6.78, 2.36) 0.341 1.000 −8.58 (−13.48, −3.68) 0.001 * 0.006 * −5.72 (−10.02, −1.42) 0.009 * 0.085
 IN −3.73 (−8.60, 1.15) 0.133 1.000 −7.11 (−12.20, −2.01) 0.007 * 0.059 −4.79 (−9.18, −0.40) 0.033 * 0.294
 OS −2.24 (−6.03, 1.55) 0.246 1.000 −0.16 (−4.36, 4.05) 0.942 1.000 −0.11 (−3.93, 3.72) 0.956 1.000
 OT −1.61 (−5.06, 1.83) 0.357 1.000 0.17 (−3.62, 3.96) 0.931 1.000 −1.07 (−4.48, 2.35) 0.539 1.000
 OI −3.54 (−7.29, 0.21) 0.064 0.577 −2.20 (−6.34, 1.93) 0.295 1.000 −4.57 (−8.10, −1.03) 0.012 * 0.104
 ON −2.21 (−6.51, 2.10) 0.314 1.000 −4.62 (−9.25, 0.00) 0.050 0.452 −2.96 (−6.97, 1.06) 0.149 1.000
NFL, μm
 C −0.32 (−1.02–0.38) 0.366 1.000 −0.26 (−1.03, 0.51) 0.511 1.000 −0.05 (−0.73, 0.64) 0.896 1.000
 IS −0.29 (−1.46–0.88) 0.625 1.000 −0.71 (−1.99, 0.58) 0.280 1.000 −0.16 (−1.33, 1.01) 0.786 1.000
 IT −0.17 (−0.63–0.30) 0.478 1.000 0.38 (−0.13, 0.90) 0.145 1.000 0.35 (−0.14, 0.83) 0.159 1.000
 II 0.56 (−0.49–1.62) 0.296 1.000 −0.53 (−1.64, 0.58) 0.346 1.000 −0.19 (−1.28, 0.91) 0.738 1.000
 IN 0.25 (−0.54–1.04) 0.535 1.000 −0.41 (−1.20, 0.39) 0.316 1.000 0.01 (−0.73, 0.76) 0.970 1.000
 OS 0.27 (−1.53–2.06) 0.769 1.000 −0.25 (−2.10, 1.60) 0.790 1.000 −0.63 (−2.43, 1.17) 0.490 1.000
 OT 0.64 (−0.02–1.30) 0.059 0.528 0.23 (−0.32, 0.77) 0.418 1.000 0.20 (−0.32, 0.72) 0.446 1.000
 OI −0.45 (−2.80–1.90) 0.707 1.000 0.41 (−1.97, 2.80) 0.734 1.000 0.30 (−1.81, 2.41) 0.778 1.000
 ON 1.14 (−1.42–3.70) 0.380 1.000 −1.81 (−4.37, 0.75) 0.166 1.000 −0.34 (−2.65, 1.98) 0.775 1.000
GCL, μm
 C −0.23 (−1.47–1.00) 0.711 1.000 −0.03 (−1.39, 1.34) 0.969 1.000 0.36 (−0.90, 1.62) 0.572 1.000
 IS −0.92 (−2.76–0.91) 0.323 1.000 −2.49 (−4.54, −0.45) 0.017 * 0.155 −1.98 (−3.74, −0.23) 0.027 * 0.243
 IT 0.10 (−1.73–1.93) 0.912 1.000 −2.34 (−4.30, −0.37) 0.020 * 0.179 −1.77 (−3.57, 0.04) 0.055 0.496
 II −0.60 (−2.42–1.23) 0.520 1.000 −2.05 (−4.03, −0.07) 0.043 * 0.383 −1.96 (−3.74, −0.18) 0.031 * 0.277
 IN −1.09 (−3.14–0.97) 0.300 1.000 −1.77 (−4.01, 0.47) 0.121 1.000 −1.89 (−3.88, 0.10) 0.063 0.569
 OS −0.49 (−1.59–0.60) 0.377 1.000 0.37 (−0.84, 1.59) 0.545 1.000 −0.85 (−1.92, 0.23) 0.121 1.000
 OT −0.33 (−1.59–0.92) 0.600 1.000 0.54 (−0.87, 1.94) 0.451 1.000 −0.01 (−1.27, 1.24) 0.983 1.000
 OI −1.46 (−2.62–−0.31) 0.014 * 0.122 −0.58 (−1.77, 0.62) 0.344 1.000 −0.73 (−1.73, 0.28) 0.156 1.000
 ON −0.71 (−1.88–0.46) 0.232 1.000 −0.67 (−1.96, 0.61) 0.302 1.000 −0.52 (−1.64, 0.60) 0.362 1.000
IPL, μm
 C −0.53 (−1.58–0.52) 0.322 1.000 −0.27 (−1.39, 0.85) 0.636 1.000 0.08 (−0.94, 1.11) 0.873 1.000
 IS −0.68 (−1.83–0.46) 0.241 1.000 −1.60 (−2.84, −0.35) 0.012 * 0.110 −1.29 (−2.40, −0.18) 0.023 * 0.210
 IT −0.41 (−1.59–0.76) 0.487 1.000 −1.90 (−3.15, −0.66) 0.003 * 0.025 * −1.44 (−2.61, −0.26) 0.017 * 0.154
 II −0.32 (−1.45–0.81) 0.578 1.000 −1.35 (−2.58, −0.11) 0.033 * 0.299 −1.04 (−2.15, 0.08) 0.068 0.610
 IN −0.71 (−2.01–0.59) 0.284 1.000 −1.35 (−2.76, 0.07) 0.063 0.569 −1.22 (−2.49, 0.05) 0.059 0.528
 OS −0.24 (−1.03–0.55) 0.551 1.000 0.46 (−0.43, 1.35) 0.312 1.000 −0.59 (−1.34, 0.17) 0.128 1.000
 OT −0.14 (−0.97–0.70) 0.745 1.000 −0.15 (−1.07, 0.76) 0.742 1.000 −0.35 (−1.19, 0.49) 0.417 1.000
 OI −0.90 (−1.70–−0.10) 0.028 * 0.255 −0.40 (−1.24, 0.44) 0.353 1.000 −0.84 (−1.57, −0.11) 0.025 * 0.221
 ON −0.41 (−1.28–0.46) 0.356 1.000 −0.71 (−1.66, 0.25) 0.146 1.000 −0.69 (−1.50, 0.12) 0.097 0.870
NFL + GCL,
 C −0.55 (−2.37–1.27) 0.551 1.000 −0.28 (−2.30, 1.73) 0.781 1.000 0.32 (−1.52, 2.16) 0.734 1.000
 IS −1.21 (−3.86–1.43) 0.366 1.000 −3.20 (−6.15, −0.25) 0.034 * 0.303 −2.14 (−4.71, 0.42) 0.101 0.908
 IT −0.06 (−1.97–1.85) 0.947 1.000 −1.95 (−3.99, 0.09) 0.060 0.543 −1.42 (−3.31, 0.48) 0.141 1.000
 II −0.04 (−2.63–2.55) 0.978 1.000 −2.58 (−5.37, 0.21) 0.069 0.625 −2.15 (−4.73, 0.43) 0.103 0.924
 IN −0.84 (−3.38–1.71) 0.517 1.000 −2.18 (−4.91, 0.56) 0.119 1.000 −1.87 (−4.34, 0.59) 0.136 1.000
 OS −0.22 (−2.73–2.28) 0.860 1.000 0.13 (−2.46, 2.71) 0.924 1.000 −1.48 (−3.97, 1.01) 0.244 1.000
 OT 0.30 (−1.29–1.89) 0.707 1.000 0.76 (−0.89, 2.41) 0.363 1.000 0.19 (−1.33, 1.71) 0.808 1.000
 OI −1.91 (−5.02–1.19) 0.226 1.000 −0.16 (−3.28, 2.95) 0.917 1.000 −0.42 (−3.13, 2.29) 0.759 1.000
 ON 0.43 (−2.62–3.48) 0.780 1.000 −2.48 (−5.66, 0.69) 0.125 1.000 −0.86 (−3.73, 2.02) 0.558 1.000
GCL + IPL,
 C −0.76 (−2.95–1.42) 0.493 1.000 −0.30 (−2.67, 2.08) 0.806 1.000 0.45 (−1.75, 2.64) 0.690 1.000
 IS −1.61 (−4.45–1.23) 0.266 1.000 −4.09 (−7.23, −0.95) 0.011 * 0.098 −3.27 (−5.99, −0.55) 0.019 * 0.167
 IT −0.31 (−3.15–2.53) 0.829 1.000 −4.24 (−7.28, −1.21) 0.006 * 0.057 −3.20 (−6.03, −0.38) 0.026 * 0.238
 II −0.92 (−3.75–1.92) 0.526 1.000 −3.40 (−6.49, −0.31) 0.031 * 0.282 −3.00 (−5.76, −0.24) 0.034 * 0.302
 IN −1.80 (−4.99–1.40) 0.270 1.000 −3.12 (−6.61, 0.38) 0.081 0.725 −3.11 (−6.20, −0.02) 0.048 * 0.436
 OS −0.73 (−2.57–1.10) 0.432 1.000 0.83 (−1.21, 2.87) 0.422 1.000 −1.43 (−3.20, 0.33) 0.110 0.991
 OT −0.47 (−2.41–1.47) 0.633 1.000 0.39 (−1.77, 2.54) 0.725 1.000 −0.36 (−2.32, 1.59) 0.717 1.000
 OI −2.36 (−4.26–−0.46) 0.015 * 0.135 −0.97 (−2.95, 1.00) 0.333 1.000 −1.57 (−3.25, 0.11) 0.067 0.605
 ON −1.12 (−3.08–0.84) 0.262 1.000 −1.38 (−3.55, 0.79) 0.211 1.000 −1.21 (−3.05, 0.64) 0.200 1.000
NFL + IPL,
 C −0.85 (−2.50–0.80) 0.311 1.000 −0.53 (−2.31, 1.26) 0.562 1.000 0.04 (−1.58, 1.66) 0.963 1.000
 IS −0.98 (−2.99–1.04) 0.341 1.000 −2.30 (−4.52, −0.09) 0.042 * 0.376 −1.45 (−3.45, 0.54) 0.153 1.000
 IT −0.58 (−1.88–0.72) 0.378 1.000 −1.52 (−2.88, −0.16) 0.029 * 0.260 −1.09 (−2.41, 0.23) 0.106 0.950
 II 0.24 (−1.67–2.16) 0.804 1.000 −1.88 (−3.95, 0.20) 0.076 0.683 −1.22 (−3.19, 0.75) 0.223 1.000
 IN −0.46 (−2.30–1.38) 0.622 1.000 −1.75 (−3.70, 0.19) 0.077 0.695 −1.21 (−2.98, 0.57) 0.181 1.000
 OS 0.03 (−2.20–2.26) 0.979 1.000 0.21 (−2.11, 2.52) 0.859 1.000 −1.22 (−3.43, 1.00) 0.280 1.000
 OT 0.50 (−0.73–1.73) 0.422 1.000 0.07 (−1.14, 1.28) 0.907 1.000 −0.15 (−1.30, 1.01) 0.804 1.000
 OI −1.35 (−4.12–1.43) 0.340 1.000 0.01 (−2.79, 2.82) 0.992 1.000 −0.54 (−3.01, 1.93) 0.669 1.000
 ON 0.73 (−2.09–3.56) 0.609 1.000 −2.51 (−5.40, 0.38) 0.088 0.792 −1.02 (−3.65, 1.61) 0.444 1.000
GCC, μm
 C −1.08 (−3.86–1.69) 0.443 1.000 −0.55 (−3.58, 2.48) 0.720 1.000 0.40 (−2.38, 3.18) 0.777 1.000
 IS −1.90 (−5.51–1.71) 0.302 1.000 −4.79 (−8.80, −0.79) 0.019 * 0.174 −3.43 (−6.94, 0.07) 0.055 0.491
 IT −0.48 (−3.39–2.43) 0.746 1.000 −3.86 (−6.95, −0.77) 0.015 * 0.131 −2.86 (−5.76, 0.05) 0.054 0.483
 II −0.36 (−3.92–3.21) 0.845 1.000 −3.93 (−7.79, −0.06) 0.046 * 0.417 −3.18 (−6.73, 0.36) 0.078 0.705
 IN −1.55 (−5.22–2.13) 0.408 1.000 −3.52 (−7.50, 0.46) 0.082 0.742 −3.10 (−6.65, 0.46) 0.088 0.788
 OS −0.46 (−3.55–2.62) 0.768 1.000 0.58 (−2.66, 3.83) 0.724 1.000 −2.07 (−5.11, 0.98) 0.183 1.000
 OT 0.17 (−2.09–2.42) 0.885 1.000 0.61 (−1.78, 3.00) 0.615 1.000 −0.16 (−2.38, 2.06) 0.888 1.000
 OI −2.81 (−6.47–0.85) 0.132 1.000 −0.56 (−4.26, 3.13) 0.765 1.000 −1.26 (−4.47, 1.94) 0.438 1.000
 ON 0.02 (−3.50–3.55) 0.989 1.000 −3.19 (−6.93, 0.56) 0.095 0.855 −1.54 (−4.90, 1.82) 0.367 1.000

Note: Age and sex were controlled and adjusted in the multiple variable regression models.

Figure 4.

Figure 4

In the ETDRS grid map, the color-coded sectors showed significant decreased full retina thickness in different groups of neuropsychological severity in Alzheimer’s dementia. C: center; IS: inner superior; IT: inner temporal; II: inner inferior; IN: inner nasal; OS: outer superior; OT: outer temporal; OI: outer inferior; ON: outer nasal; MMSE: Mini-Mental State Examination, CDR: Clinical Dementia Rating.

4. Discussion

The present study showed that retinal thickness was thinner in patients with AD in comparison to that of people without AD. Significant differences were found in the thickness of full macular layers and IPL thickness, but not in NFL thickness. In addition, major differences were found at the inner sectors of the macula in the ETDRS grid map.

The retina shares similarities with the brain, and the concept of the retina as an exceptionally convenient window by which to assess the neuronal and vascular changes in the central nervous system (CNS) started decades ago. Various retinal changes in AD have been investigated in the last three decades. In 1986, Hinton et al. discovered in postmortem histological research that AD patients possessed prevalent axonal degeneration, decline in a variety of retinal ganglion cells (RCGs), and decline in the thickness of the retinal nerve fiber layer (RNFL) compared to those of age-matched controls [15]. This finding was further supported by electrophysiological research revealing unusual patterns in the electroretinogram as feasible documentation of RGC degeneration in AD [16,17]. Despite several inconsistencies, most studies revealed alterations in visual function, including visual acuity, contrast sensitivity, and color perception, as well as structural change such as a decrease in RNFL and GCL thickness and the pattern of ERG amplitude, a reduction of optic nerve fibers, and an increase of glial reactivity and cell loss in AD retinas. Several animal studies on the analysis of the OCT images showed a statistically significant thinning of the nerve fiber layer in AD mouse retinas compared to wild type controls, though there were some inconsistent findings in different reports. The inconsistency might be due to the young age of the tested animals or may suggest an initial inflammatory response that may lead to cell death and the consequent reduction in thickness later on [18,19,20]. Through the advance of ocular imaging technology, the current OCT technology allows high-resolution in vivo cross-sectional images as well as quantifiable and reproducible calculations of the macula and the possibility of ocular biomarkers for systemic diseases, including AD.

Results of the present study were compatible with previous reports demonstrating thinning of the retina, although in variable sectors [21,22,23,24,25,26,27]. Considering the pathological change of the retina in AD shows the deposition of amyloid β plaques in the retinal ganglion complex (RGC), which is a combination of nerve fibers, ganglion cells, and inner plexiform layers, RGC is the major structure affected in AD patients. Due to centrifugal distribution, there is more RGC in the inner part of the retina, which helps to explain the result showing change of full layer thickness, IPL, and GCL + IPL in the inner circle of macula related to thinner thickness due to AD. In our study, AD patients tended to have thinner thickness of full layer thickness, IPL, and GC-IPL, rather than solely NFL, and the result was similar to several reports [28,29]. The proportion GC-IPL is approximately 50% in RGC, whose cell bodies are over 10 to 20 times the diameter of their axons [29], and we hypothesized that GC-IPL might be more vulnerable to the damage in Alzheimer’s dementia (AD). In addition, though reduction of RNFL thickness in AD was reported [23], the evidence of dynamic changes of NFL and GC-IPL during AD progression was never reported [30]. A recently published convolutional neural network (CNN) to detect symptomatic Alzheimer’s dementia (AD) using a combination of multimodal retinal images and patient data also showed that GC-IPL maps were the most useful single inputs for prediction [31].

It is highly expected that changes in retinal thickness of AD patients correlates with the severity of AD. Currently, the relationship between macular thickness and the severity of cognitive function impairment is still not well established. A systematic review supported the presence of RNFL thinning and mild cognitive impairment (MCI), particularly amnestic MCI, though less remarkable than the associations with AD [32]. The present study included only AD patients who had received treatment, but not those with MCI. We categorized the AD patients into mild AD and moderate-to-severe AD based on MMSE scores and CDR grading. After multivariable linear regression, the MMSE scores correlated positively with macular thickness, and the association between CDR grading and macular thickness was much more significant. The significantly changed areas were at the inner circle of the macula, compatible with general analysis of AD patients versus controls. Variable sensitivity and specificity of MMSE scores may be due to patients’ age, sex, or education status [33], while for CDR scores, the sensitivity and specificity were reported to be as high as 87% and 99% [34], respectively. Thus, CDR scores may be a more objective and consistent parameter for evaluating the clinical cognitive condition. Since patients in the present study were missing certain MMSE or CDR data, the whole missing data group presented similar findings as those with AD. We speculated that patients in the missing data group might the more severe AD patients who could not complete the psychiatric and cognitive examinations. In other words, our results might support a possible association between AD and retinal thinning, which would be very helpful in monitoring the disease course or even treatment response. Integrated with brain imaging and biomarker and neuropsychological assessment, the eye could potentially improve AD risk assessment, detection, and monitoring [35].

This study has several limitations. First, it was a retrospective study, and OCT images taken around the time of AD diagnosis were retrieved, suggesting there may be a gap between the diagnosis or disease severity and the images taken. Some patients might not visit neurology department and ophthalmology department around the same time, and this was the possible reason leading to the gap in the retrospective study. Retrospective design also limits generalization of results to other populations and does not allow the ruling out of selection bias. Second, nearly 40% of cognitive examinations were missing from patients’ records at the time of switching from paper to electronic medical records or were simply not done. We are planning to conduct a further prospective longitudinal study where the patients may receive OCT imaging in a timelier manner during the initial diagnosis of AD, which will allow associations between the trend of macular thickness and the change of MMSE or CDR scores within several years to be detected prospectively. However, it should be noted that the present study included large case numbers, and the other systemic or ocular diseases were excluded or matched before analysis.

5. Conclusions

In conclusion, significant retinal thinning was noted in the retinas of AD patients, especially in full retinal layers and inner plexiform layers at the inner circle of the macula. Results of this study support that macular thickness may be a useful biomarker of the disease severity of AD. Retinal images may be non-invasive, low-cost surrogates for AD.

Acknowledgments

This work was supported by Kaohsiung Medical University Hospital (KMUHIRB-E(I)-20200405). The authors thank the help from the Division of Medical Statistics and Bioinformatics, Kaohsiung Medical University Hospital for providing administrative support.

Appendix A

Table A1.

Characteristics of subgroup analysis stratified by MMSE and CDR scores. N: numbers of patients; y/o: years-old; MMSE: Mini-Mental State Examination, CDR: Clinical Dementia Rating; SD: standard deviation; 95% CI: 95% confidence interval; p-value < 0.05 is considered as statistically significant (*).

MMSE Score CDR Score
Group 1
(MMSE ≥ 18)
Group 2
(MMSE < 18)
Group 3
(Missing Data)
Group 1
(CDR = 0.5)
Group 2
(CDR = 1, 2)
Group 3
(Missing Data)
N, %/Mean ± SD N, %/Mean ± SD N, %/Mean ± SD p-Value N, %/Mean ± SD N, %/Mean ± SD N, %/Mean ± SD p-Value
N N = 87 N = 37 N = 51 N = 58 N = 48 N = 69
Age (y/o) 75.97 ± 10.91 80.76 ± 6.76 76.53 ± 11.60 0.059 77.76 ± 9.66 77.15 ± 10.85 76.62 ± 11.07 0.834
Age, category
 <65 7 (8.05%) 1 (2.70%) 8 (15.69%) 0.004 * 4 (6.90%) 7 (14.58%) 5 (7.25%) 0.024 *
 65~74 29 (33.33%) 3 (8.11%) 13 (25.49%) 13 (22.41%) 6 (12.50%) 26 (37.68%)
 ≥75 51 (58.62%) 33 (89.19%) 30 (58.82%) 41 (70.69%) 35 (72.92%) 38 (55.07%)
Gender
 Male 34 (39.08%) 14 (37.84%) 20 (39.22%) 0.990 23 (39.66%) 23 (47.92%) 22 (31.88%) 0.214
 Female 53 (60.92%) 23 (62.16%) 31 (60.78%) 35 (60.34%) 25 (52.08%) 47 (68.12%)

Appendix B

Table A2.

Between-group comparisons via subgroup analysis stratified by MMSE and CDR scores. N: numbers of patients; MMSE: Mini-Mental State Examination; CDR: Clinical Dementia Rating; NFL: nerve fiber layers; GCL: ganglion cell layer; IPL: inner plexiform layer; GCC: ganglion cell complex (NFL + GCL + IPL); SD: standard deviation; 95% CI: 95% confidence interval; p-value < 0.05 is considered as statistically significant (*).

MMSE Group CDR Group
Group 1
(MMSE ≥ 18)
Group 2
(MMSE < 18)
Group 3
(Missing Data)
Group 1 (CDR = 0.5) Group 2
(CDR = 1, 2, 3)
Group 3
(Missing Data)
Mean ± SD Mean ± SD Mean ± SD p-Value Mean ± SD Mean ± SD Mean ± SD p-Value
N N = 87 N = 37 N = 51 N = 58 N = 48 N = 69
Full, μm
 C 258.70 ± 20.90 256.20 ± 24.82 257.20 ± 18.12 0.810 257.00 ± 20.71 256.10 ± 21.46 259.40 ± 20.96 0.663
 IS 323.40 ± 17.00 324.40 ± 15.89 320.90 ± 15.94 0.571 323.70 ± 17.46 321.00 ± 15.18 323.40 ± 16.49 0.646
 IT 312.70 ± 15.61 311.60 ± 16.35 308.60 ± 16.00 0.338 313.30 ± 16.15 308.70 ± 15.15 311.40 ± 16.14 0.334
 II 320.20 ± 17.82 322.00 ± 16.56 314.60 ± 15.71 0.081 321.90 ± 17.66 316.10 ± 15.86 318.50 ± 17.35 0.210
 IN 327.00 ± 19.19 329.60 ± 17.46 323.40 ± 14.51 0.246 327.70 ± 19.95 324.90 ± 16.47 326.70 ± 16.45 0.715
 OS 283.30 ± 13.83 287.40 ± 13.79 281.50 ± 16.49 0.162 282.10 ± 13.10 284.30 ± 14.50 284.40 ± 16.19 0.640
 OT 269.90 ± 12.53 271.80 ± 13.48 268.40 ± 15.04 0.494 269.10 ± 12.89 271.20 ± 13.04 269.70 ± 14.36 0.719
 OI 273.60 ± 13.21 274.90 ± 15.27 269.40 ± 15.10 0.146 272.50 ± 13.95 274.00 ± 14.89 271.80 ± 14.32 0.717
 ON 300.50 ± 15.99 300.70 ± 15.03 294.90 ± 15.72 0.099 299.70 ± 15.98 297.30 ± 15.68 299.30 ± 15.99 0.724
NFL, μm
 C 11.51 ± 2.30 11.43 ± 2.48 11.84 ± 2.44 0.655 11.45 ± 2.20 11.58 ± 2.36 11.71 ± 2.54 0.827
 IS 25.70 ± 4.48 25.14 ± 3.65 24.59 ± 4.47 0.339 25.31 ± 3.90 24.94 ± 4.09 25.43 ± 4.82 0.825
 IT 18.34 ± 1.53 19.08 ± 1.99 18.88 ± 2.48 0.100 18.33 ± 1.70 18.92 ± 1.83 18.75 ± 2.23 0.268
 II 24.30 ± 4.04 25.59 ± 4.23 23.82 ± 4.16 0.128 25.02 ± 3.85 24.00 ± 2.95 24.25 ± 4.99 0.404
 IN 21.71 ± 3.15 22.03 ± 3.00 21.22 ± 2.77 0.436 21.90 ± 3.33 21.35 ± 2.37 21.61 ± 3.15 0.653
 OS 39.34 ± 6.17 41.05 ± 6.48 36.88 ± 7.53 0.013 * 39.48 ± 6.52 38.79 ± 5.38 38.71 ± 7.87 0.795
 OT 20.91 ± 2.00 21.57 ± 2.17 20.76 ± 3.63 0.324 21.31 ± 3.43 20.88 ± 1.79 20.84 ± 2.29 0.556
 OI 38.69 ± 7.68 40.30 ± 10.51 36.80 ± 7.29 0.141 37.88 ± 9.43 38.75 ± 7.30 38.80 ± 8.02 0.798
 ON 50.07 ± 7.96 51.24 ± 9.26 45.51 ± 8.74 0.002 * 50.31 ± 9.85 47.38 ± 6.99 49.00 ± 8.75 0.228
GCL, μm
 C 13.89 ± 4.48 13.89 ± 4.99 13.73 ± 4.13 0.977 13.52 ± 3.79 13.85 ± 4.22 14.10 ± 5.17 0.766
 IS 47.25 ± 5.58 47.97 ± 5.67 45.37 ± 6.17 0.079 47.60 ± 5.49 46.04 ± 5.81 46.80 ± 6.11 0.389
 IT 42.57 ± 6.15 41.16 ± 5.66 39.49 ± 6.78 0.021 * 42.71 ± 5.90 40.33 ± 5.27 40.99 ± 7.24 0.129
 II 46.00 ± 6.11 46.35 ± 6.05 43.75 ± 6.63 0.076 46.28 ± 5.94 44.90 ± 5.64 45.06 ± 7.03 0.446
 IN 46.18 ± 6.68 47.16 ± 6.07 44.35 ± 6.60 0.114 46.24 ± 6.22 45.63 ± 6.00 45.70 ± 7.30 0.862
 OS 31.77 ± 4.22 32.95 ± 4.11 30.18 ± 4.62 0.011 * 31.43 ± 4.10 32.19 ± 4.68 31.22 ± 4.48 0.489
 OT 32.56 ± 4.19 33.14 ± 5.03 31.43 ± 5.63 0.226 31.97 ± 4.30 32.81 ± 4.96 32.36 ± 5.20 0.671
 OI 30.18 ± 4.09 29.81 ± 4.53 29.88 ± 3.90 0.866 29.45 ± 4.66 30.25 ± 4.15 30.33 ± 3.58 0.437
 ON 35.57 ± 3.69 35.76 ± 3.90 34.49 ± 4.85 0.245 35.16 ± 3.90 35.10 ± 4.22 35.55 ± 4.26 0.805
IPL, μm
 C 19.22 ± 3.90 18.84 ± 4.09 19.12 ± 3.54 0.880 18.78 ± 3.76 19.13 ± 3.46 19.38 ± 4.13 0.679
 IS 37.10 ± 3.78 37.32 ± 3.34 36.61 ± 3.83 0.632 37.43 ± 3.54 36.50 ± 3.43 37.00 ± 3.99 0.437
 IT 37.94 ± 4.14 37.16 ± 4.05 36.90 ± 4.73 0.347 38.22 ± 4.11 36.81 ± 3.45 37.30 ± 4.92 0.224
 II 36.74 ± 4.04 36.76 ± 3.70 35.65 ± 4.15 0.261 36.93 ± 3.69 35.94 ± 3.79 36.33 ± 4.41 0.437
 IN 38.41 ± 4.26 38.24 ± 3.41 37.67 ± 4.15 0.576 38.47 ± 3.78 37.85 ± 3.73 38.12 ± 4.50 0.739
 OS 25.94 ± 2.97 26.65 ± 2.85 24.82 ± 2.89 0.013 * 25.69 ± 2.72 26.33 ± 3.28 25.43 ± 2.96 0.270
 OT 30.06 ± 2.56 30.35 ± 3.38 29.33 ± 3.58 0.252 29.97 ± 2.72 29.96 ± 2.93 29.83 ± 3.46 0.960
 OI 24.69 ± 2.69 24.65 ± 2.82 24.10 ± 3.21 0.480 24.33 ± 3.02 24.77 ± 2.80 24.48 ± 2.82 0.729
 ON 27.30 ± 2.77 27.30 ± 2.83 26.29 ± 3.57 0.142 27.17 ± 2.94 26.79 ± 3.32 27.01 ± 2.99 0.817
NFL + GCL
 C 25.39 ± 6.27 25.32 ± 6.98 25.57 ± 6.18 0.982 24.97 ± 5.51 25.44 ± 6.05 25.81 ± 7.26 0.759
 IS 72.95 ± 8.82 73.11 ± 8.19 69.96 ± 9.33 0.121 72.91 ± 8.16 70.98 ± 8.81 72.23 ± 9.58 0.535
 IT 60.92 ± 6.21 60.24 ± 6.27 58.37 ± 7.47 0.093 61.03 ± 6.34 59.25 ± 5.33 59.74 ± 7.68 0.351
 II 70.30 ± 9.14 71.95 ± 9.26 67.57 ± 9.45 0.077 71.29 ± 8.78 68.90 ± 7.68 69.30 ± 10.74 0.349
 IN 67.90 ± 8.84 69.19 ± 8.04 65.57 ± 7.99 0.117 68.14 ± 8.40 66.98 ± 7.31 67.30 ± 9.37 0.764
 OS 71.11 ± 8.31 74.00 ± 8.91 67.06 ± 11.02 0.002 * 70.91 ± 9.20 70.98 ± 8.08 69.93 ± 10.86 0.792
 OT 53.47 ± 4.87 54.70 ± 6.24 52.20 ± 7.65 0.161 53.28 ± 6.26 53.69 ± 5.55 53.20 ± 6.43 0.908
 OI 68.87 ± 10.54 70.11 ± 13.18 66.69 ± 9.66 0.317 67.33 ± 12.83 69.00 ± 9.78 69.13 ± 9.96 0.609
 ON 85.64 ± 9.20 87.00 ± 11.30 80.00 ± 11.05 0.002 * 85.47 ± 10.85 82.48 ± 9.13 84.55 ± 11.16 0.338
GCL + IPL
 C 33.10 ± 8.15 32.73 ± 8.83 32.84 ± 7.37 0.967 32.29 ± 7.30 32.98 ± 7.42 33.48 ± 9.05 0.712
 IS 84.36 ± 9.03 85.30 ± 8.60 81.98 ± 9.19 0.182 85.03 ± 8.66 82.54 ± 8.77 83.80 ± 9.49 0.368
 IT 80.52 ± 9.85 78.32 ± 9.28 76.39 ± 10.72 0.064 80.93 ± 9.51 77.15 ± 8.16 78.29 ± 11.55 0.133
 II 82.74 ± 9.92 83.11 ± 9.43 79.39 ± 10.02 0.110 83.21 ± 9.38 80.83 ± 9.07 81.39 ± 10.90 0.422
 IN 84.60 ± 10.58 85.41 ± 9.18 82.02 ± 9.84 0.227 84.71 ± 9.57 83.48 ± 9.46 83.81 ± 11.07 0.807
 OS 57.71 ± 7.04 59.59 ± 6.88 55.00 ± 6.94 0.008 * 57.12 ± 6.68 58.52 ± 7.70 56.65 ± 7.10 0.368
 OT 62.62 ± 6.50 63.49 ± 8.12 60.76 ± 8.88 0.212 61.93 ± 6.85 62.77 ± 7.55 62.19 ± 8.37 0.850
 OI 54.87 ± 6.64 54.46 ± 7.09 53.98 ± 6.86 0.756 53.78 ± 7.46 55.02 ± 6.78 54.81 ± 6.17 0.582
 ON 62.87 ± 6.18 63.05 ± 6.62 60.78 ± 7.77 0.165 62.33 ± 6.48 61.90 ± 7.40 62.57 ± 6.72 0.873
NFL + IPL
 C 30.72 ± 5.81 30.27 ± 6.26 30.96 ± 5.70 0.861 30.22 ± 5.57 30.71 ± 5.41 31.09 ± 6.40 0.712
 IS 62.80 ± 7.20 62.46 ± 5.61 61.20 ± 7.26 0.413 62.74 ± 6.25 61.44 ± 6.40 62.43 ± 7.78 0.608
 IT 56.29 ± 4.51 56.24 ± 4.26 55.78 ± 5.65 0.829 56.55 ± 4.68 55.73 ± 3.52 56.06 ± 5.64 0.673
 II 61.03 ± 7.14 62.35 ± 6.99 59.47 ± 7.58 0.177 61.95 ± 6.56 59.94 ± 5.93 60.58 ± 8.55 0.339
 IN 60.13 ± 6.73 60.27 ± 5.49 58.88 ± 5.85 0.462 60.36 ± 6.41 59.21 ± 5.13 59.72 ± 6.79 0.635
 OS 65.29 ± 7.44 67.70 ± 7.88 61.71 ± 9.32 0.003 * 65.17 ± 7.91 65.13 ± 7.01 64.14 ± 9.58 0.741
 OT 50.97 ± 3.47 51.92 ± 4.81 50.10 ± 5.91 0.185 51.28 ± 5.03 50.83 ± 3.57 50.67 ± 4.90 0.753
 OI 63.38 ± 9.31 64.95 ± 12.07 60.90 ± 9.18 0.150 62.21 ± 11.32 63.52 ± 8.95 63.28 ± 9.52 0.761
 ON 77.37 ± 8.68 78.54 ± 10.67 71.80 ± 10.15 0.001 * 77.48 ± 10.44 74.17 ± 8.28 76.01 ± 10.35 0.230
GCC
 C 44.61 ± 9.95 44.16 ± 10.87 44.69 ± 9.46 0.967 43.74 ± 9.02 44.56 ± 9.25 45.19 ± 11.20 0.719
 IS 110.10 ± 12.07 110.40 ± 10.77 106.60 ± 12.31 0.191 110.30 ± 11.07 107.50 ± 11.54 109.20 ± 12.88 0.469
 IT 98.86 ± 9.93 97.41 ± 9.55 95.27 ± 11.32 0.144 99.26 ± 9.89 96.06 ± 8.02 97.04 ± 11.94 0.255
 II 107.00 ± 12.77 108.70 ± 12.46 103.20 ± 12.99 0.105 108.20 ± 12.01 104.80 ± 11.02 105.60 ± 14.61 0.351
 IN 106.30 ± 12.75 107.40 ± 11.02 103.20 ± 11.25 0.209 106.60 ± 11.80 104.80 ± 10.66 105.40 ± 13.16 0.739
 OS 97.06 ± 10.46 100.60 ± 11.04 91.88 ± 13.04 0.002 * 96.60 ± 11.19 97.31 ± 10.59 95.36 ± 13.02 0.662
 OT 83.53 ± 7.07 85.05 ± 9.31 81.53 ± 10.71 0.165 83.24 ± 8.58 83.65 ± 8.02 83.03 ± 9.55 0.933
 OI 93.56 ± 12.60 94.76 ± 15.19 90.78 ± 12.08 0.318 91.66 ± 15.12 93.77 ± 11.97 93.61 ± 11.96 0.630
 ON 112.90 ± 10.65 114.30 ± 13.28 106.30 ± 13.15 0.002 * 112.60 ± 12.16 109.30 ± 11.36 111.60 ± 13.17 0.369

Author Contributions

Conceptualization: S.-J.S., Y.-C.C. and Y.-H.Y.; methodology: S.-J.S. and H.-M.H.; software: H.-M.H.; data collection: C.-C.K., H.-C.C.; writing—original draft preparation: C.-C.K.; writing—review and editing: S.-J.S., Y.-H.Y. and H.-M.H.; supervision: S.-J.S. and Y.-H.Y. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB-E(I)-20200405).

Informed Consent Statement

Patient consent was waived since this research was retrospective in design using already existing information.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Funding Statement

This work was supported by the Kaohsiung Medical University Hospital (KMUHIRB-E(I)-20200405).

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Blennow K., de Leon M.J., Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:387–403. doi: 10.1016/S0140-6736(06)69113-7. [DOI] [PubMed] [Google Scholar]
  • 2.Prince M., Albanese E., Guerchet M. Ph.D. Thesis. King’s College London; London, UK: 2014. World Alzheimer Report 2014. Dementia and Risk Reduction: An Analysis of Protective and Modifiable Risk Factors. [Google Scholar]
  • 3.Jack C.R., Jr., Bennett D.A., Blennow K., Carrillo M.C., Dunn B., Haeberlein S.B., Holtzman D.M., Jagust W., Jessen F., Karlawish J., et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sabbagh M.N., Lue L.F., Fayard D., Shi J. Increasing Precision of Clinical Diagnosis of Alzheimer’s Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data. Neurol. Ther. 2017;6((Suppl. S1)):S83–S95. doi: 10.1007/s40120-017-0069-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.London A., Benhar I., Schwartz M. The retina as a window to the brain—From eye research to CNS disorders. Nat. Rev. Neurol. 2013;9:44–53. doi: 10.1038/nrneurol.2012.227. [DOI] [PubMed] [Google Scholar]
  • 6.Kim J.-I., Kang B.-H. Decreased retinal thickness in patients with Alzheimer’s disease is correlated with disease severity. PLoS ONE. 2019;14:e0224180. doi: 10.1371/journal.pone.0224180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cheung C.Y., Mok V., Foster P.J. Retinal imaging in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 2021;92:983–994. doi: 10.1136/jnnp-2020-325347. [DOI] [PubMed] [Google Scholar]
  • 8.Maruko I., Arakawa H., Koizumi H., Izumi R., Sunagawa H., Iida T. Age-Dependent Morphologic Alterations in the Outer Retinal and Choroidal Thicknesses Using Swept Source Optical Coherence Tomography. PLoS ONE. 2016;11:e0159439. doi: 10.1371/journal.pone.0159439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study Report Number 1. Arch Ophthalmol. 1985;103:1796–1806. doi: 10.1001/archopht.1985.01050120030015. [DOI] [PubMed] [Google Scholar]
  • 10.Xu Q., Li Y., Cheng Y., Qu Y. Assessment of the effect of age on macular layer thickness in a healthy Chinese cohort using spectral-domain optical coherence tomography. BMC Ophthalmol. 2018;18:169. doi: 10.1186/s12886-018-0842-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Graessel E., Stemmer R., Eichenseer B., Pickel S., Donath C., Kornhuber J., Luttenberger K. Non-pharmacological, multicomponent group therapy in patients with degenerative dementia: A 12-month randomizied, controlled trial. BMC Med. 2011;9:129. doi: 10.1186/1741-7015-9-129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Chen S.Y., Yang Y.H., Ouyang W.C. Probable Early-onset Alzheimer’s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies. Taiwan. J. Psychiatry. 2011;25:45–49. [Google Scholar]
  • 13.Anderson T.W., Darling D.A. A Test of Goodness of Fit. J. Am. Stat. Assoc. 1954;49:765. doi: 10.1080/01621459.1954.10501232. [DOI] [Google Scholar]
  • 14.Shaffer J.P. Multiple hypothesis testing. Annu. Rev. Psychol. 1995;46:561–584. doi: 10.1146/annurev.ps.46.020195.003021. [DOI] [Google Scholar]
  • 15.Hinton D.R. Optic-nerve degeneration in Alzheimer’s disease. N. Engl. J. Med. 1986;315:485–487. doi: 10.1056/NEJM198608213150804. [DOI] [PubMed] [Google Scholar]
  • 16.Katz B. Abnormal pattern electroretinogram in Alzheime’s disease: Evidence for retinal ganglion cell degeneration? Ann. Neurol. 1989;26:221–225. doi: 10.1002/ana.410260207. [DOI] [PubMed] [Google Scholar]
  • 17.Trick G.L., Barris M.C., Bickler-Bluth M. Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. Ann. Neurol. 1989;26:226–231. doi: 10.1002/ana.410260208. [DOI] [PubMed] [Google Scholar]
  • 18.Harper D.J., Augustin M., Lichtenegger A., Gesperger J., Himmel T., Muck M., Merkle C.W., Eugui P., Kummer S., Woehrer A., et al. Retinal analysis of a mouse model of Alzheimer’s disease with multi-contrast optical coherence tomography. Neurophotonics. 2020;7:015006. doi: 10.1117/1.NPh.7.1.015006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Batista A., Guimarães P., Martins J., Moreira P.I., Ambrósio A.F., Castelo-Branco M., Serranho P., Bernardes R. Normative mice retinal thickness: 16-month longitudinal characterization of wild-type mice and changes in a model of Alzheimer’s disease. Front. Aging Neurosci. 2023;15:1161847. doi: 10.3389/fnagi.2023.1161847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ferreira H., Serranho P., Guimarães P., Trindade R., Martins J., Moreira P.I., Ambrósio A.F., Castelo-Branco M., Bernardes R. Stage-independent biomarkers for Alzheimer’s disease from the living retina: An animal study. Sci. Rep. 2022;12:13667. doi: 10.1038/s41598-022-18113-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ito Y., Sasaki M., Takahashi H., Nozaki S., Matsuguma S., Motomura K., Ui R., Shikimoto R., Kawasaki R., Yuki K., et al. Quantitative Assessment of the Retina Using OCT and Associations with Cognitive Function. Ophthalmology. 2019;127:107–118. doi: 10.1016/j.ophtha.2019.05.021. [DOI] [PubMed] [Google Scholar]
  • 22.Jones-Odeh E., Hammond C.J. How strong is the relationship between glaucoma, the retinal nerve fibre layer, and neuro-degenerative diseases such as Alzheimer’s disease and multiple sclerosis? Eye. 2015;29:1270–1284. doi: 10.1038/eye.2015.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Cunha J.P., Proença R., Dias-Santos A., Almeida R., Águas H., Alves M., Papoila A.L., Louro C., Castanheira-Dinis A. OCT in Alzheimer’s disease: Thinning of the RNFL and superior hemiretina. Graefes. Arch. Clin. Exp. Ophthalmol. 2017;255:1827–1835. doi: 10.1007/s00417-017-3715-9. [DOI] [PubMed] [Google Scholar]
  • 24.den Haan J., Verbraak F.D., Visser P.J., Bouwman F.H. Bouwman, Retinal thickness in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimer’s Dement. Diagn. Assess. Dis. Monit. 2017;6:162–170. doi: 10.1016/j.dadm.2016.12.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zhang Y., Wang Y., Shi C., Shen M., Lu F. Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer’s disease. Transl. Neurodegener. 2021;10:6. doi: 10.1186/s40035-021-00230-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Shao Y., Jiang H., Wei Y., Shi Y., Shi C., Wright C.B., Sun X., Vanner E.A., Rodriguez A.D., Lam B.L., et al. Visualization of Focal Thinning of the Ganglion Cell-Inner Plexiform Layer in Patients with Mild Cognitive Impairment and Alzheimer’s Disease. J. Alzheimer’s Dis. 2018;64:1261–1273. doi: 10.3233/JAD-180070. [DOI] [PubMed] [Google Scholar]
  • 27.Garcia-Martin E., Bambo M.P., Marques M.L., Satue M., Otin S., Larrosa J.M. Ganglion cell layer measurements correlate with disease severity in patients with Alzheimer’s disease. Acta Ophthalmol. 2016;94:e454–e459. doi: 10.1111/aos.12977. [DOI] [PubMed] [Google Scholar]
  • 28.Mutlu U., Colijin J.M., Ikram M.A., Bonnemaijer P.W.M., Licher S., Wolters F.J., Tiemeier H., Koudstaal P.J., Klaver C.C.W., Ikram M.K., et al. Faculty Opinions recommendation of Association of Retinal Neurodegeneration on Optical Coherence Tomography With Dementia: A Population-Based Study. JAMA Neurol. 2018;75:1256–1263. doi: 10.1001/jamaneurol.2018.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Choi S.H., Park S.J., Kim N.R. Macular Ganglion Cell-Inner Plexiform Layer Thickness Is Associated with Clinical Progression in Mild Cognitive Impairment and Alzheimer’s Disease. PLoS ONE. 2016;11:e0162202. doi: 10.1371/journal.pone.0162202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lad E.M., Mukherjee D., Stinnett S.S., Cousins S.W., Potter G.G., Burke J.R., Farsiu S., Whitson H. Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer’s disease. PLoS ONE. 2018;13:e0192646. doi: 10.1371/journal.pone.0192646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Wisely C.E., Wang D., Henao R., Grewal D.S., Thompson A.C., Robbins C.B., Yoon S.P., Soundararajan S., Polascik B.W., Burke J.R., et al. Convolutional neural network to identify symptomatic Alzheimer’s disease using multimodal retinal imaging. Br. J. Ophthalmol. 2022;106:388–395. doi: 10.1136/bjophthalmol-2020-317659. [DOI] [PubMed] [Google Scholar]
  • 32.Noah A.M., Almghairbi D., Moppett I.K. Optical coherence tomography in mild cognitive impairment—Systematic review and meta-analysis. Clin. Neurol. Neurosurg. 2020;196:106036. doi: 10.1016/j.clineuro.2020.106036. [DOI] [PubMed] [Google Scholar]
  • 33.Li H., Jia J., Yang Z. Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study. J. Alzheimer’s Dis. 2016;53:487–496. doi: 10.3233/JAD-160119. [DOI] [PubMed] [Google Scholar]
  • 34.Huang H., Tseng Y., Chen Y., Chen P., Chiu H. Diagnostic accuracy of the Clinical Dementia Rating Scale for detecting mild cognitive impairment and dementia: A bivariate meta-analysis. Int. J. Geriatr. Psychiatry. 2021;36:239–251. doi: 10.1002/gps.5436. [DOI] [PubMed] [Google Scholar]
  • 35.Gupta V.B., Chitranshi N., den Haan J., Mirzaei M., You Y., Lim J.K., Basavarajappa D., Godinez A., Di Angelantonio S., Sachdev P., et al. Retinal changes in Alzheimer’s disease-integrated prospects of imaging, functional and molecular advances. Prog. Retin. Eye Res. 2021;82:100899. doi: 10.1016/j.preteyeres.2020.100899. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.


Articles from Journal of Personalized Medicine are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES